Related Experiment Video
Updated: Jun 8, 2025
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.4K
Initial Evaluation of lncRNA A2M-AS1 Gene Expression in Multiple Sclerosis Patients
Shaghayegh Mohammadi1, Tahereh Sadeghiyan1, Mohammad Rezaei2
1Department of Genetics, Faculty of Biology Sciences and Technology, Shahid Ashrafi Esfahani, Isfahan, Iran.
Advanced Biomedical Research
|November 8, 2024
Summary
Reduced expression of the long non-coding RNA (lncRNA) A2M-AS1 is linked to multiple sclerosis (MS). This lncRNA A2M-AS1 shows potential as a diagnostic biomarker for identifying MS in patients.
Area of Science:
- Neuroscience
- Genetics
- Biomarker Discovery
Background:
- Multiple sclerosis (MS) is a leading global neurodegenerative disease.
- Gene expression profiling is crucial for understanding and preventing diseases like MS.
- Non-coding RNAs are increasingly recognized for their role in disease pathogenesis and as potential diagnostic tools.
Purpose of the Study:
- To investigate the expression of the long non-coding RNA (lncRNA) A2M-AS1 in patients with MS.
- To evaluate the potential of lncRNA A2M-AS1 as a diagnostic biomarker for MS.
- To explore gene interactions involving non-coding RNAs in MS.
Main Methods:
- Utilized microarray data from the GEO database to analyze A2M-AS1 expression in MS patients.
- Performed lncRNA-mRNA interaction analysis using the lncRRisearch database.
- Validated A2M-AS1 expression changes in 20 MS and 20 healthy samples via quantitative reverse transcriptase polymerase chain reaction (RT-qPCR).
Main Results:
- Found a significant decrease in A2M-AS1 gene expression in MS patient samples compared to healthy controls.
- Receiver operating characteristic (ROC) analysis indicated that lncRNA A2M-AS1 serves as a reliable diagnostic biomarker for distinguishing MS patients.
- Bioinformatic and laboratory analyses confirmed the findings.
Conclusions:
- Reduced expression of lncRNA A2M-AS1 is associated with an increased risk of developing MS.
- lncRNA A2M-AS1 is a promising diagnostic biomarker for multiple sclerosis.
- Further investigation into non-coding RNAs may offer new avenues for MS diagnosis and therapy.
More Related Videos
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
01:32RNA Splicing
56.0K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.0K